Results 161 to 170 of about 36,124 (280)

Liquid biopsy: a step forward in laboratory medicine

Advances in Laboratory Medicine
Díaz-Lagares Angel, Jiménez Wladimiro
doaj   +1 more source

Using ctDNA to Inform Adjuvant Therapy for Urologic Malignancies. [PDF]

Cancers (Basel)
Goradia R, Goodstein T, Sundi D, Sood A, Dason S, Singer EA.   +5 more
europepmc   +1 more source

Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA group

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Relapse after chimeric antigen receptor (CAR) T‐cell therapy in large B‐cell lymphoma (LBCL) is associated with a dismal prognosis. Although Phase 3 trials have established CAR T‐cells as standard second‐line (2L) therapy, outcomes and optimal management after relapse in this setting remain unknown because no real‐world data are currently ...
Pierre Sesques, Guillaume Manson, Guillaume Cartron, François‐Xavier Gros, Franck Morschhauser, Cristina Castilla‐Llorente, Gabriel Brisou, Pierre Bories, Catherine Thieblemont, Laurianne Drieu La Rochelle, Benoit Tessoulin, Axel André, Cedric Rossi, Jérôme Paillassa, Stephanie Guidez, Antoine Capes, Laura Herbreteau, Sylvain Choquet, Jacques‐Olivier Bay, Adrien Chauchet, Laure Lebras, Fabien Claves, Julie Abraham, Jean‐Valère Malfuson, Marie‐Thérèse Rubio, Justine Decroocq, Luc‐Matthieu Fornecker, Gandhi Damaj, Ludovic Fouillet, Magalie Joris, Michael Loschi, Olivier Hermine, Hadia Hafirassou, Emelie Van Zele, Vivien Dupont, Steven Le Gouill, Roch Houot, Vincent Camus   +37 more
wiley   +1 more source

Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma. [PDF]

Clin Cancer Res
Ansstas G, Khaddour K, Sudhaman S, Lin K, Budde GL, Poklepovic A, Doonan BP, Mooradian MJ, Sullivan RJ, Ma VT, Rosiecki J, Liu S, Drengler R, Flora DB, Beasley GM, Rhodin KE, Hyngstrom JR, Brunsgaard EK, Ortiz JB, George GV, Krainock M, Liu MC, Tan A.   +22 more
europepmc   +1 more source

The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B‐Cell Lymphoma (CLSG‐CNS‐01): A Randomized, Multicenter, Prospective Phase 3 Trial

Hematological Oncology, Volume 44, Issue 3, May 2026.
ABSTRACT The randomized, multicenter, prospective Phase 3 trial (NCT02777736) evaluated central nervous system (CNS) prophylaxis using either intravenous (i.v.) or intrathecal (i.t.) methotrexate (MTX) in diffuse large B‐cell lymphoma (DLBCL). Treatment consisted of six cycles of R‐CHOP + 2xR or DA‐EPOCH‐R + 2xR. Patients with intermediate or high‐risk
H. Mocikova, L. Gaherova, T. Jancarkova, A. Suri, A. Janikova, K. Steinerova, D. Belada, R. Pytlik, J. Duras, M. Trnkova, P. Blahovcova, T. Kozak, M. Trneny   +12 more
wiley   +1 more source

Circulating Tumor DNA Monitoring in Peptide Receptor Radionuclide Therapy-Treated Patients With Gastroenteropancreatic Neuroendocrine Tumors. [PDF]

JCO Precis Oncol
Bogdani C, Karimi A, Li R, Atkinson EC, Oberstein PE, Siolas D.   +5 more
europepmc   +1 more source

Detection of recurrent endometrial cancer via DNA methylation analysis of cervicovaginal self‐samples and urine

International Journal of Cancer, Volume 158, Issue 9, Page 2491-2500, 1 May 2026.
What's new? Post‐treatment surveillance for endometrial cancer aims to detect recurrence early, potentially improving outcome. Emerging evidence suggests that DNA methylation analysis of self‐collected cervicovaginal and urine samples is a promising approach.
Annick J. Nouwens, Mirte Schaafsma, Nienke E. van Trommel, Jenneke C. Kasius, Renske D. M. Steenbergen, Maaike C. G. Bleeker   +5 more
wiley   +1 more source

Circulating Tumor DNA as a Biomarker in Pancreatic Cancer: Clinical Applications and Challenges. [PDF]

Clin Transl Gastroenterol
Yao G, Zhang Y, Li H, Teng L, Man Y, Wang S, Liu C, Fan Y, Chen D.   +8 more
europepmc   +1 more source

Breaking the ctDNA sensitivity barrier

, 2017
O estudo da biologia molecular do cancro tem permitido avanços científicos com impacto na prática clínica, mudando o paradigma de abordagem terapêutica convencional, sistémica, para uma abordagem personalizada. No entanto, a caracterização molecular de tumores sólidos só é possível através da biopsia do tecido, uma estratégia altamente invasiva com ...
openaire   +1 more source

Requiring Caution in the Interpretation of Donor‐Derived Cell‐Free DNA Levels During Cancer Treatment in a Kidney Transplant Recipient.: A Case Report

IJU Case Reports, Volume 9, Issue 3, May 2026.
ABSTRACT Introduction Donor‐derived cfDNA (dd‐cfDNA) indicates allograft rejection when > 1% of total cfDNA, but tumor‐derived cfDNA can interfere in cancer patients. Case Presentation A 61‐year‐old male kidney transplant recipient with metastatic renal cell carcinoma (RCC) initiated avelumab and axitinib.
Nanaka Katsurayama, Toshihito Hirai, Yu Kijima, Hiroki Ishihara, Hironori Fukuda, Kazuya Omoto, Tomokazu Shimizu, Masashi Inui, Hideki Ishida, Toshio Takagi   +9 more
wiley   +1 more source